Francesca DeMartino has been named senior vice president of BD investor relations for the company, effective Nov. 29.
In this role, DeMartino will lead all aspects of communicating progress of the BD2025 strategy to investors and the financial community, including the company’s initiatives that drive shareholder value. DeMartino will report to Chris DelOrefice, executive vice president and chief financial officer for BD. She succeeds Kristen Stewart who has been named senior vice president of enterprise strategy and insights for BD.
“Francesca is an accomplished leader with a long track record of success in investor relations, including extensive experience in the medical technology industry,” said DelOrefice. “She will lead BD’s efforts to highlight key milestones as we deliver on our strategy to drive growth through innovation.”
DeMartino has more than 20 years of combined experience in investor relations, communications and corporate finance, with her most recent position as vice president of investor relations at Medtronic. During her tenure, the function received IR Magazine awards for Best Overall Investor Relations and Best Investor Relations in Health Care. She had previously served as vice president of corporate communications and vice president of global communications for the Diabetes Group. Prior to joining Medtronic, DeMartino held positions of increasing responsibility at Johnson & Johnson, OMRIX Biopharmaceuticals, Macrocure Ltd, GCI Group and The Ruth Group. She began her career at Deutsche Bank AG as a financial analyst in the Health Care Investment Banking Group.
DeMartino holds a Bachelor of Arts in international and area studies from the University of California, Berkeley and a minor in business administration from the Walter A. Haas School of Business.